|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
FY2018
12 months to Dec 31, 2018
|
|
|---|---|---|---|---|---|
| Cash Flows Used in Operating Activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation | |||||
| Accretion (amortization) of premiums and discounts on investments | |||||
| Stock-based compensation | |||||
| Gain on remeasurement of the lease liability | |||||
| Change in fair value of warrant liabilities | |||||
| Transaction costs allocable to warrant liabilities | |||||
| Non-cash lease expense | |||||
| Series A convertible preferred stock issued for research and development related to asset acquisition | |||||
| Changes in operating assets and liabilities: | |||||
| Receivables from collaborations | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued liabilities | |||||
| Lease liability | |||||
| Net cash used in operating activities | |||||
| Cash Flows Provided by (Used in) Investing Activities | |||||
| Purchases of investments | |||||
| Proceeds from the sale and maturity of investments | |||||
| Purchase of property and equipment | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash Flows Provided by Financing Activities | |||||
| Proceeds from issuance of common stock upon public offering, net | |||||
| Proceeds from issuance of common stock through at-the-market offerings, net | |||||
| Issuance costs related to the issuance of convertible preferred stock | |||||
| Proceeds from stock option exercises and employee stock plan purchases | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
Loading...
